MYCN and glioblastoma: Similar to Felgenhauer et al.29 where they found synergism between BET and Aurora A inhibitors irrespective of MYCN status of neuroblastoma cells, we could demonstrate a strong synergism in all four tested GBM cell lines, irrespective of whether they had high (JQ1-sensitive) or low (JQ1-resistant) MYCN expression (Fig. 5d).